Drug reference
margetuximab
chimeric IgG1, HER2 inhibitor · anticancer
chimeric IgG1, HER2 inhibitoranticancer
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Margetuximab is a chimeric IgG1-targeting HER2.
Indications
metastatic HER2-positive breast cancer (after two or more prior anti-HER2 regimens, in combination with chemotherapy)
Side effects
Serious
- left ventricular dysfunction
Related guidelines
Ask House about margetuximab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team